

Attorney Docket No.: 5636.210-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Nielsen et al.

Confirmation No: 6089

Serial No.: 10/038,723

Group Art Unit: 1652

Filed: December 21, 2001

Examiner: Rao

For: Glucoamylase Variants

CERTIFICATE OF FACSIMILE TRANSMISSION

Commissioner for Patents
Washington, DC 20231


Sir:

I hereby certify that the attached correspondence comprising:

1. Response to Restriction Requirement

was sent to the United States Patent Office by telefax to the attention of Examiner Rao , fax number (703) 305-3014.

Respectfully submitted,



Date: October 24, 2003

Lourdes Ayala
Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(212) 840-0097

**RECEIVED
CENTRAL FAX CENTER**

OCT 24 2003

OFFICIAL

Attorney Docket No.: 5636.210-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Nielsen et al.

Confirmation No: 6089

Serial No.: 10/038,723

Group Art Unit: 1652

Filed: December 21, 2001

Examiner: Rao

For: Glucoamylase Variants

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:


This paper is filed in response to the Office Action mailed October 9, 2002 that made an election of species requirements. Applicants were requested to elect a single disclosed species, i.e., a single amino acid position modification.

In response to these requirements, Applicants hereby elect the species of a variant having a modification at a position corresponding to position 402.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this response or application.

Respectfully submitted,

Date: October 24, 2003


Jason I. Garbell, Reg. No. 44,116
Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(212) 840-0097

**RECEIVED
CENTRAL FAX CENTER**

OCT 24 2003

OFFICIAL